2020
PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker
Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Scientific Reports 2020, 10: 10943. PMID: 32616904, PMCID: PMC7331689, DOI: 10.1038/s41598-020-68071-6.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine neoplasmsNeuroendocrine neoplasmsPAM immunoreactivityPAM stainingStage-independent predictorUnpredictable clinical behaviorRisk of deathIndividual patient prognosisRare epithelial tumorsHigh-grade tumorsPotential prognostic biomarkerMedian timeSmall bowelAvailable biomarkersTumor sizeDisease stageClinical associationsGrade tumorsClinical behaviorPatient prognosisPrognostic biomarkerEpithelial tumorsTherapy selectionSurvival implicationsPatients
2012
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry & Molecular Morphology 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/pai.0b013e31821c821c.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBreast NeoplasmsEsophageal NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMaleMiddle AgedReceptor, ErbB-2Retrospective StudiesStomach NeoplasmsUnited StatesConceptsGastroesophageal junction cancerHER2-positive adenocarcinomaGastroesophageal junction carcinomaJunction cancerHER2 expressionHER2 statusClinical Oncology/CollegeHER2-positive gastricGastroesophageal junction adenocarcinomaGastric Cancer TrialIntestinal-type adenocarcinomaPrimary tumor siteMembranous staining patternHER2/CEP17 ratioPrimary gastric adenocarcinomaTissue microarray approachASCO/CAPHER2 gene amplificationHER2 protein expressionJunction adenocarcinomaDiffuse adenocarcinomaGastroesophageal junctionPatient survivalTherapeutic optionsIntestinal type
2010
Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma
Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate‐ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer 2010, 116: 5179-5187. PMID: 20665497, DOI: 10.1002/cncr.25481.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCarbonic Anhydrase IXCarbonic AnhydrasesCell HypoxiaCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHumansImmunohistochemistryMaleMiddle AgedPancreatic NeoplasmsPoly(ADP-ribose) PolymerasesPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTetrahydrofolate DehydrogenaseTissue Array AnalysisConceptsProgression-free survivalOverall survivalPoly adenosine diphosphate-ribose polymerasePancreatic adenocarcinomaImproved OSImmunohistochemical expressionHypoxia markersImproved overall survivalCyclin-dependent kinase inhibitor 2AExpression of p16INK4aCarbonic anhydrase IXAdjuvant chemotherapyCurative resectionMedian survivalImproved survivalMargin statusClinical outcomesPrimary tumorPancreatic cancerUnivariate analysisSurgical specimensImmunohistochemical stainingTissue microarrayPositive stainingPatients